Table 1 Baseline characteristics of patients and healthy volunteers
NSCLC | N = 11 |
|---|---|
Age | |
 Median | 64 (52–73) |
Sex | |
 Male | 9 (69%) |
ECOG performance-status score | |
 0 | 8 (61%) |
 1 | 4 (31%) |
 2 | 1 (8%) |
Histology | |
 Adenocarcinoma | 9 (69%) |
 Squamous | 4 (31%) |
PDL-1 expresssion | |
  > 50% | 11 (85%) |
  ≤ 50% | 2 (15%) |
Treatment | |
 Anti-PD-L1 | 10 (77%) |
 Anti-PD-L1 + chemo | 2 (15%) |
 Anti-PD-L1 + Anti CTLA-4 + chemo | 1 (8%) |
Melanoma | N = 9 |
|---|---|
Age | |
 Median | 61 (45–81) |
Sex | |
 Male | 6 (67%) |
ECOG performance-status score | |
 0 | 5 (56%) |
 1 | 3 (33%) |
 2 | 1 (11%) |
Cancer Type | |
 Cutaneous | 8 (89%) |
 Uveal | 1 (11%) |
BRAF | |
 Wild Type | 7 (78%) |
 Mutant | 1 (11%) |
 Unknown | 1 (11%) |
Treatement | |
 Anti-PD-L1 | 3 (33%) |
 Anti-PD-L1 + Anti CTLA-4 | 6 (67%) |
Healthy volunteers (HV) | N=7 |
|---|---|
Age | Â |
 Median | 37 (27–42) |
Sex | Â |
 Male | 3 (43%) |